Century Therapeutics, Inc. (IPSC)

Market Cap	44.13M
Revenue (ttm)	6.59M
Net Income (ttm)	-126.57M
Shares Out	86.05M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,099
Open	0.5494
Previous Close	0.5484
Day's Range	0.5129 - 0.5583
52-Week Range	0.5129 - 4.4280
Beta	1.75
Analysts	Strong Buy
Price Target	4.67 (+810.51%)
Earnings Date	Mar 19, 2025

About IPSC

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineer...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: IPSC
• Website: https://www.centurytx.com

Financial Performance

In 2024, Century Therapeutics's revenue was $6.59 million, an increase of 194.81% compared to the previous year's $2.24 million. Losses were -$126.57 million, -7.40% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 810.51% from the latest price.

Price Target

$4.67

(810.51% upside)

Analyst Consensus: Strong Buy